Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01288963 · ClinicalTrials.gov registry record
IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma
A clinical trial, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- 153
- Enrollment target
NCT01288963: Completed study, sponsored by Beth Israel Deaconess Medical Center.
NCT01288963 is a clinical trial that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 153 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01288963 has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- 153 participants
- Enrollment target
Study Summary
The purpose of this study is to determine which participants with melanoma have a better response to IL-2 and to identify markers that may predict response to IL-2 by collecting participant information (for example; cancer diagnosis and history, prior treatments for cancer, etc.) blood and tumor samples prior to treatment and tumor measurements after treatment.
Interventions
- DRUG IL-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2010-02 |
| Est. Completion | 2020-12 |
What the finished NCT01288963 record still lists
NCT01288963 is an observational study that tracks outcomes without assigning an intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which IL-2 is the first listed.
NCT01288963 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01288963 about?
NCT01288963 is a clinical study titled "IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma". The purpose of this study is to determine which participants with melanoma have a better response to IL-2 and to identify markers that may predict response to IL-2 by collecting participant information (for example; cancer diagnosis and history, prior treatments for cancer, etc.) blood and tumor sam...
What is the current status of trial NCT01288963?
This trial is currently completed. The enrollment target is 153 participants. The study started on 2010-02. Estimated completion is 2020-12.
What interventions are being tested in trial NCT01288963?
The interventions under investigation include: IL-2 (DRUG).
Who is sponsoring clinical trial NCT01288963?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283265 · 153 participants · NA
Neurophysiological Mechanisms of Language Comprehension
- NCT05554393 · 153 participants · Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- NCT05584501 · 153 participants · NA
ETE Interventions in the Dental Setting
- NCT05714839 · 153 participants · Phase 1
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia